NCT03739541View on ClinicalTrials.gov

Benznidazole Absorption, Metabolism and Excretion Study

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

July 16, 2018

Primary Completion Date

September 2, 2018

Study Completion Date

September 2, 2018

Conditions

Healthy Male Subjects

Interventions

DRUG

[14C]-Benznidazole

A single dose level of 100 mg; 200 μCi (7.4 MBq)

Trial Locations (1)

LS2 9LH

Covance, Leeds

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Insud Pharma

INDUSTRY

lead

Exeltis France

UNKNOWN

NCT03739541 - Benznidazole Absorption, Metabolism and Excretion Study | Biotech Hunter | Biotech Hunter